Clinical trial
Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1
NCT03738878
Study timeline
Study start (actual)2018-11-15Date precision: day
Registry last updated2025-08-03
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Hypertensionunresolved
Interventions
ValsartanDRUG · verified · RxNorm: valsartan
LCZ696DRUG
BradykininDRUG
Substance PDRUG
BNPDRUG
SitagliptinDRUG · verified · RxNorm: sitagliptin
Sponsors & collaborators
Vanderbilt University Medical Centerlead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03738878 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.